Eli Lilly’s Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers.
Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and Drug Administration.It’s a sign that pharmaceutical firm Lilly is making strides to improve the supply issues that have plagued the sector.
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
Eli Lilly weight-loss drug shortage ends, shaking up telehealth
Compounded versions of popular weight-loss drugs attracted telehealth companies that marketed services to connect patients with healthcare providers.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
Drugs prescribed for weight loss, such as Mounjaro, Ozempic, Wegovy, and Zepbound, have been popular, expensive, and in short supply. To meet the demand, health providers like Hims & Hers had ...
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
Shares of Hims & Hers Health (HIMS) sank Thursday after the Food and Drug Administration (FDA) said Eli Lilly’s (LLY) popular weight-loss treatments, Mounjaro and Zepbound, were no longer on its ...
Lilly's weight-loss, diabetes drugs no longer in shortage, pressuring Hims and Hers' stock
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding manufacturing.
Lilly's weight-loss drug removed from FDA's shortage list
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs.
End of Zepbound Shortage Threatens $1 Billion Knockoff Weight-Loss Shot Industry
Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss drugs are scrambling to figure out if they’ll still have access after US regulators signaled an end to their unfettered use.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...